Background Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. Objectives To identify predictors of treatment failure of scabies in ambulatory populations. Methods This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. Results In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2Á15, 95% confidence interval (CI) 1Á22-3Á77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10Á2. 95% CI 4Á49-23Á2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4Á31, 95% CI 1Á89-9Á84); (iv) absence of decontamination of furnishings (OR 8Á72, 95% CI 3Á50-21Á8), in particular sofa and cushions (OR 5Á90, 95% CI 2Á34-14Á9), mattresses (OR 4Á16, 95% CI 1Á35-12Á8) or car seats (OR 6Á57, 95% CI 3Á27-13Á2) and (v) absence of written documents explaining treatment modalities (OR 5Á18, 95% CI 2Á57-10Á4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6Á62, 95% CI 2Á71-16Á2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3Á51, 95% CI 1Á55-7Á95) and (iii) absence of decontamination of furniture with acaricides (OR 5Á81, 95% CI 1Á96-16Á7). Conclusions Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
Summary
Background Treatment failure, which occurs in about one-third of cases, is considered as a major factor in the increasing incidence of scabies in developed countries. Objectives To identify predictors of treatment failure of scabies in ambulatory populations. Methods This multicentre study compared the clinical characteristics and treatment modalities between a group of patients with scabies treated successfully and another group who were not cured 3 months after antiscabies treatment. Results In total 210 patients with a diagnosis of scabies were included, comprising 98 patients in the treatment success group and 112 in the treatment failure group. The main risk factors for treatment failure were (i) the use of only one type of treatment, topical benzyl benzoate (BB) or oral ivermectin, vs. the combination of both treatments [odds ratio (OR) 2Á15, 95% confidence interval (CI) 1Á22-3Á77]; (ii) the use of a single intake (vs. two) of oral ivermectin (OR 10Á2. 95% CI 4Á49-23Á2); (iii) intake of ivermectin during a meal vs. on an empty stomach (OR 4Á31, 95% CI 1Á89-9Á84); (iv) absence of decontamination of furnishings (OR 8Á72, 95% CI 3Á50-21Á8), in particular sofa and cushions (OR 5Á90, 95% CI 2Á34-14Á9), mattresses (OR 4Á16, 95% CI 1Á35-12Á8) or car seats (OR 6Á57, 95% CI 3Á27-13Á2) and (v) absence of written documents explaining treatment modalities (OR 5Á18, 95% CI 2Á57-10Á4). In multivariate analysis, treatment failure was mainly associated with (i) use of a single intake (vs. two) of ivermectin (OR 6Á62, 95% CI 2Á71-16Á2); (ii) use of BB alone vs. two intakes of ivermectin (OR 3Á51, 95% CI 1Á55-7Á95) and (iii) absence of decontamination of furniture with acaricides (OR 5Á81, 95% CI 1Á96-16Á7). Conclusions Use of topical BB alone and a single intake (vs. two) of ivermectin are predictors of treatment failure.
What's already known about this topic?
• Scabies is a major public health problem worldwide.
• Developing countries account for the majority of cases, but an increasing incidence of scabies has been reported in developed countries.
• Treatment failure is considered a major factor in the increasing incidence of scabies in developed countries.
• Risk factors for antiscabies treatment failure, such as dementia and bedridden status, have been identified in hospitalized populations and are not relevant in ambulatory patients.
What does this study add?
• This study, which was conducted in a large cohort of ambulatory patients, highlights several risk factors.
• A single intake of ivermectin is the major cause of treatment failure in scabies.
• The combination of one topical application of benzyl benzoate and two intakes of oral ivermectin results in the lowest rate of treatment failure.
• Not disinfecting fomites increases the risk of treatment failure.
Scabies is a major public health problem worldwide, affecting approximately 130 million people in the world.
1 Developing countries account for the majority of cases, with prevalence rates between 13% and 46%. 2 In these populations, overcrowding, poor hygiene and poverty are the main factors for reinfestation and treatment failure. [2] [3] [4] The prevalence of scabies is estimated at between 2% and 4% in Europe and the U.S.A. 3, 4 Treatment failure, which occurs in about one-third of cases, is considered the major factor in the increasing incidence of scabies reported in the recent past in developed countries such as France and the U.K.
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Predictors of treatment failure in developed countries have been assessed exclusively in a series of hospitalized patients. 9 These predictors -immune deficiency, dementia and bedridden status -are less relevant in ambulatory patients. As these latter represent the majority of cases of scabies, we conducted a study to identify predictors of treatment failure of scabies in ambulatory patients.
Patients and methods

Design and population
This observational study was conducted from June 2011 to December 2013 in the dermatology department of Rouen University Hospital and in 14 private dermatology practices in Normandy, a region in the north-west of France. Consecutive patients were included if they fulfilled the following criteria: (i) clinical diagnosis of scabies; (ii) agreement to fill in a standardized form to collect data on the patient's living conditions, family status and treatment modalities; and (iii) agreement to return for a follow-up visit 3 months after treatment initiation. This study was approved by the institutional review board of Rouen University Hospital, no. E2014-24.
Diagnosis of scabies was performed clinically. It was considered definitive when mites or burrows were seen using dermatoscopy, and highly presumptive when the following signs of scabies were observed: presence of burrows associated with erythematous papules and/or pruritus with nocturnal predominance, and typical localizations such as the hands, flexural surface of the wrist, elbows, genitalia, umbilicus, nipples and buttocks.
Two groups of patients were defined at the time the study was designed. The treatment success group included patients who were referred for a first episode of scabies; success corresponds to complete healing defined by absence of both clinical signs and itching, and no clinical features of scabies at the 3-month follow-up visit. The second group, the treatment failure group, included two subgroups of patients: (i) patients referred for a first episode of scabies and who had persistent clinical features of scabies at the 3-month follow-up visit, and (ii) patients who were referred for clinical symptoms of scabies despite an initial antiscabies treatment prescribed in the previous 3 months, including topical application(s) of benzyl benzoate (BB) and/or oral ivermectin, which were the only two labelled antiscabies treatments at the time of the study in France. Antiscabies treatments were left to each investigator's preference in this observational study.
Data collection
Data were recorded from standardized forms that patients had to fill in. The first set of items referred to patients and their living conditions: age, sex, rural or urban environment, place of residence, family status, sleeping habits, mode of childcare, socioeconomic status, relevant comorbidities and duration of symptoms before the diagnosis. A second set of items referred to treatment modalities for the first episode of scabies, including type of medication(s) used (BB and/or ivermectin alone or in association), number of repetitions of the treatment, use of acaricides to decontaminate the furniture (spraying A-PAR, containing Neo-Pynamin forte 4Á3 g and Sumithrin 4Á3 g on sofas, cushions, car seats and mattresses for 10-12 h) and the number of the patient's relatives simultaneously treated. Finally, patients were asked to mention if they had received a prefilled electronic document explaining in detail the treatment modalities. Patients referred for a first episode of scabies filled in the form at the 3-month follow-up visit, whereas patients referred for scabies despite an initial antiscabies treatment prescribed in the previous 3 months filled in the form at the inclusion visit.
Statistical analysis
All of these data were compared between patients from the treatment failure group and patients from the treatment success group. The target sample size was 231 patients to detect an odds ratio (OR) of 2Á5 for a prevalence of 30% of patients having treatment failure, with a 90% power and for a twosided type I error of 5%.
The groups were compared using Student's t-test for quantitative characteristics and Pearson's v 2 -test or Fisher's exact test as appropriate for categorical characteristics. All P-values were two tailed and P-values < 0Á05 were considered to be significant. Univariate analysis was performed using GraphPad Prism software (version 6Á0; GraphPad Software, La Jolla, CA, U.S.A.). Variables with P < 0Á20 in the univariate analysis were analysed by backward multivariate analysis in order to determine independent risk factors associated with treatment failure. Variables with > 15% missing data were excluded. Final model discrimination was assessed by estimation of the area of the receiver operator characteristic curve. Goodness of fit was assessed using the Hosmer and Lemeshow goodnessof-fit test. Multivariate analysis was performed with SAS software (version 9Á3; SAS Institute Inc., Cary, NC, U.S.A.).
Results
Population of the study
We identified 231 patients of mean age 21Á7 AE 19Á5 years with a highly presumptive (n = 89) or definitive (n = 142) diagnosis of scabies. No patient recruited in hospital refused to be included. The number of patients seen by office-based dermatologists who refused to be included has not been recorded. Among the 231 patients recruited, 154 were referred for a first episode of scabies, but 21 (9%) were secondarily excluded because they did not attend the 3-month follow-up visit. Among the remaining 133 patients, complete healing (i.e. absence of clinical signs and absence of pruritus) was observed in 98 patients (73Á7%), corresponding to the treatment success group. Thirty-five patients (26Á3%) still presented clinical features of scabies at the 3-month evaluation; these constitute the treatment failure group, together with the 77 patients referred for clinical symptoms of scabies despite an initial antiscabies treatment prescribed in the previous 3
months. This corresponds to a total of 112 patients in the treatment failure group. Finally, 210 patients (107 male, 103 female) were included (Fig. 1 ).
Univariate analysis of risk factors for treatment failure
The mean age of patients (22Á8 AE 20Á6 and 22Á4 AE 18Á8 years; P = 0Á89) and their distribution with a highly presumptive (35Á7% vs. 40Á8%) or definitive diagnosis of scabies (64Á3% vs. 59Á2%, P = 0Á58) were not different between the treatment failure and treatment success groups, respectively. (Table S1 ; see Supporting Information). We did not find any difference in the socioeconomic status (worker, self-employed, civil servant, employee, student, farmer, sales representative, executive manager, craftsperson, retired person) between the treatment failure and treatment success groups (data not shown). As 21 patients (9%) were lost to follow-up, we checked that the main demographics and clinical characteristics of scabies in these patients were not statistically different from those in the rest of the study population (data not shown).
The main risk factors for treatment failure related to treatment modalities were (i) the use of only one type of treatment, topical BB or oral ivermectin, vs. the combination of both treatments (OR 2Á15, 95% CI 1Á22-3Á77); (ii) the use of (Table S2 ; see Supporting Information). Conversely, the use of one vs. two application of BB was not associated with a higher risk of relapse (OR 1Á34, 95% CI 0Á74-2Á44).
In the treatment failure group, most patients had been previously treated by a general practitioner (59 of 112 patients, 53%), whereas 23 (21%) had been previously treated by private-practice-based dermatologists and 30 (27%) by hospital-based dermatologists. Among the 133 patients who were referred for a first episode of scabies and were followed up for 3 months, 45 were seen by a private-practice-based dermatologist and 88 by a hospital-based dermatologist. The rate of treatment success (98 patients, 73Á6%) was not statistically different according to whether the patients were treated by a private-practice-based (31 of 45, 69%) or a hospital-based dermatologist (67 of 88, 76%; P = 0Á21).
Multivariate analysis
The independent predictors of treatment failure were (i) use of BB alone vs. two intakes of ivermectin (regardless of whether ivermectin was associated or not with BB) (OR 3Á51, 95% CI 1Á55-7Á95), (ii) use of a single intake of ivermectin vs. two (OR 6Á62, 95% CI 2Á71-16Á2), (iii) absence of decontamination of furniture with an acaricide (OR 5Á81, 95% CI 1Á96-16Á7), (iv) presence of other cases diagnosed in the patient's relatives (OR 2Á13, 95% CI 1Á07-4Á24) and (v) symptoms during > 1 month before diagnosis (OR 2Á95, 95% CI 1Á38-6Á32) ( Table 1) .
Discussion
This study shows that the absence of a second intake of ivermectin and the use of only one type of treatment (topical BB or oral ivermectin alone), in particular the use of BB alone, are the main predictors of treatment failure in scabies. Intake of ivermectin during a meal also appears to be a predictor of treatment failure, which is in accordance with the manufacturer's recommendations, which indicate taking ivermectin on an empty stomach. Interestingly, the number of applications of BB was not associated with an increased risk of treatment failure. Conversely, items related to the patient's socioeconomic conditions and potential financial difficulties in buying the antiscabies treatment were not associated with treatment failure.
Other strong predictors were related to the risk of recontamination, such as the absence of decontamination of furniture and presence of other cases of scabies in the patient's relatives. On the other hand, the absence of treatment of all the patient's relatives, use of childminders, absence of written information (prefilled electronic document) on treatment modalities and use of topical corticosteroids within the month following the treatment of scabies were significant only in univariate analysis.
The usefulness of decontamination of furniture is controversial in the literature and this practice is not universally adopted. However, this predictor was shown in both the univariate and multivariate analyses in our study. The risk of treatment failure associated with the absence of written information on treatment modalities, which was seen in the univariate analysis, is likely due to patients' misunderstanding of the chronology of administering oral treatments (and even more so for topical treatments) and decontaminating furnishings. The lack of standardized treatment instructions might theoretically have biased the results. However, most dermatologists in France use the forms available on the websites of the National Health Insurance and the National Health Agency, which are in fact quite similar. 10 It is likely that our findings correspond to those observed in clinical practice. The mean age of patients, 21Á7 years, was in accordance with the highest proportion of scabies in the 10-29-year-old population reported in previous epidemiological and therapeutic studies. Delay between onset of pruritus and first scabies treatment > 1 month 2Á95 (1Á38-6Á32) 0Á0054 Other known case(s) of scabies in the patient's entourage 2Á13 (1Á07-4Á24) 0Á0309 Absence of decontamination of furniture with acaricide 5Á81 (1Á96-16Á7) 0Á0014 One intake of oral ivermectin vs. two intakes (associated or not with BB) 6Á62 (2Á71-16Á2) < 0Á001 Topical BB alone vs. two intakes of ivermectin (associated or not with BB) 3Á51 (1Á55-7Á95) 0Á0026
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BB, benzyl benzoate. The area under curve of the receiver operating characteristic curve was 0Á85, 95% confidence interval 0Á80-0Á91, and the Hosmer and Lemeshow goodness-of-fit test did not show any lack of fit (P = 0Á14).
The previous predictors of treatment failure reported in the literature are immune deficiency, dementia and bedridden status, identified in an elderly population of hospitalized patients. 9 This does not correspond to the outpatient population included in the present study. A study conducted in boarding schools in Cameroon also found that the presence of other cases of scabies in the patient's close entourage was a risk factor of treatment failure. 16 The beneficial effect of a second intake of ivermectin has already been described in different therapeutic trials. [12] [13] [14] The absence of ovicidal activity of ivermectin has been suggested to explain these results. 12, 13 Conversely, as reported by Ly et al., we found no evidence that the number of topical applications of BB was a risk factor for treatment failure, regardless of whether the patient had also received ivermectin. 15 This result has potential therapeutic implications as repeated applications of BB frequently induce skin irritation. This study was performed in a large population of consecutive outpatients recruited by a panel of private-practice-based and hospital-based dermatologists, making selection bias unlikely. Additionally, the 3-month delay for assessment of treatment efficacy in the present study allowed us to take into account early relapses or recontaminations.
Various biases are possible in this study. In order to avoid selection bias, we aimed to recruit patients from both privatepractice-based and hospital-based dermatologists. This is a major difference from previous reports, which assessed prognostic factors exclusively in series of hospitalized patients. These studies identified immune deficiency, dementia and bedridden status as predictors of treatment failure. The mean age of patients in our study was 21Á7 AE 19Á5 years, which indicates that the patients recruited by both hospital-based and private-practice-based dermatologists were ambulatory patients. Accordingly, we did not see significant differences in treatment outcomes according to whether patients were seen in hospital or private practice.
Whereas most patients referred to dermatologists for treatment failure had been previously treated by a general practitioner (53%), we did not see significant differences in the treatment outcomes of patients referred for a first episode of scabies, according to whether the patients were seen in hospital or in private practice. Similarly, we did not see significant differences in the treatment outcomes according to whether the patients lived in rural or urban areas. The diagnosis of scabies was not confirmed by parasitological examination. However, diagnosis of scabies is usually performed clinically in the majority of clinical trials. [12] [13] [14] [15] 17 We cannot exclude that some patients in the treatment failure group might have intentionally or involuntarily wrongly reported how their initial treatment was performed. In particular, the fact that patients from the treatment failure group had to perform two applications of BB but may have applied only one could have biased the results, thus partly contributing to the finding that two applications of BB were not better than one. However, even systematic checking by the patient's pharmacist would not have confirmed whether the prescription had been respected or not.
Finally, we cannot exclude confusion bias. In particular, corticosteroids may have been used in patients with more extensive or severe forms of scabies. Despite the fact that permethrin is now more commonly used than BB as a topical treatment, due to its better tolerance, previous studies showed that the efficacies of both drugs were very close. 18 It is therefore likely that the same risk factors for failure of antiscabies treatment would have been identified with other antiscabies topical treatments. This study highlights the fact that a single intake of ivermectin, which is currently approved in many countries, is a major cause of treatment failure. This finding has potential implications as ivermectin is frequently prescribed instead of topical treatments in clinical practice, especially by general practitioners due to its higher convenience. 17 The combination of one application of topical BB and two intakes of oral ivermectin was associated with the highest rate of success at the 3-month follow-up (86%) in the group of 133 patients not previously treated for scabies. In summary, the association of two intakes of oral ivermectin and one application of topical treatment improves the results of treatment and might be recommended to eradicate scabies in ambulatory populations in developed countries.
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